Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

Figure 1

Immune responses measured by ELISPOT assay. ELISPOT results for all patients who had positive immune responses to the corresponding VHL peptide (spots/106 PBMC) in purple compared with the control peptide (TAX) in red: patient 2 (panel A); patient 6 (panel C); patient 3 (panel B); and patient 4 (panel D). Pre = prevaccination sample; Post V = postvaccination sample marked by the vaccine number; and F/u = follow up sample marked in months (ms) from the last post vaccine sample.

Back to article page